With a target PDUFA date of August 11th, FDA is expected to make a decision on Lykos Therapeutics’ MDMA-assisted therapy for PTSD New Drug Application (NDA) at some point this week.As we brace for a deluge of mainstream media coverage and insider reactions, I’m taking the opportunity to provide a brief assortment of notes and thoughts. I begin by providing a quick sketch of the potential decisions…
